P J Kurtin

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Indolent lymphomas of mature B lymphocytes
    Paul J Kurtin
    Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55906, USA
    Hematol Oncol Clin North Am 23:769-90. 2009
  2. ncbi Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type
    P J Kurtin
    Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Surg Pathol 25:997-1008. 2001
  3. ncbi Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis
    C M Weyand
    Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Res 2:457-63. 2000
  4. ncbi Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
    A L Feldman
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:574-80. 2009
  5. ncbi Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry
    P J Kurtin
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Pathol 112:319-29. 1999
  6. ncbi A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 28:307-14. 1998
  7. ncbi Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas
    W R Macon
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 25:285-96. 2001
  8. ncbi Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1046-52. 2012
  9. ncbi Cutaneous involvement by angioimmunoblastic T-cell lymphoma with remarkable heterogeneous Epstein-Barr virus expression
    H A Brown
    Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
    J Cutan Pathol 28:432-8. 2001
  10. ncbi Orbital lymphoma: radiotherapy outcome and complications
    S L Stafford
    Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Radiother Oncol 59:139-44. 2001

Collaborators

Detail Information

Publications19

  1. ncbi Indolent lymphomas of mature B lymphocytes
    Paul J Kurtin
    Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55906, USA
    Hematol Oncol Clin North Am 23:769-90. 2009
    ..They are distinguished from one another on clinical, morphological, phenotypic and genetic grounds. This article reviews the essential diagnostic and biologic features of these clinically indolent B cell malignancies...
  2. ncbi Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type
    P J Kurtin
    Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Surg Pathol 25:997-1008. 2001
    ....
  3. ncbi Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis
    C M Weyand
    Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Res 2:457-63. 2000
    ..B cells have a critical role in lymphoid organogenesis. Their contribution to synovial inflammation extends beyond antibody secretion and includes the activation and regulation of effector T cells...
  4. ncbi Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
    A L Feldman
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:574-80. 2009
    ..Further, due to its involvement in translocations, MUM1/IRF4 protein may play an important biologic role in some PTCLs, and might represent a possible therapeutic target...
  5. ncbi Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry
    P J Kurtin
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Pathol 112:319-29. 1999
    ..Paraffin section immunohistochemistry on sections of routinely fixed tissue can be used similarly to flow cytometry and frozen section immunohistochemistry when classifying the lymphomas of small B lymphocytes...
  6. ncbi A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 28:307-14. 1998
    ..This higher dose ProMACECytaBOM regimen can be given to older adult patients in an outpatient setting. Phase III studies would be required to determine if it produces a superior overall survival compared to other regimens...
  7. ncbi Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas
    W R Macon
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 25:285-96. 2001
    ..This group, along with the previously recognized gammadelta group, should be recognized as phenotypically heterogeneous subtypes of the same disease entity...
  8. ncbi Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1046-52. 2012
    ....
  9. ncbi Cutaneous involvement by angioimmunoblastic T-cell lymphoma with remarkable heterogeneous Epstein-Barr virus expression
    H A Brown
    Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
    J Cutan Pathol 28:432-8. 2001
    ..To our knowledge, this case is the most extensive and heterogeneous expression of EBV in cutaneous AILD T-NHL to date...
  10. ncbi Orbital lymphoma: radiotherapy outcome and complications
    S L Stafford
    Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Radiother Oncol 59:139-44. 2001
    ..Late relapse occurs in sites other than the treated orbit, even in patients with early-stage disease. Doses 35 Gy or higher result in significant late complications and are therefore not indicated for patients with low-grade tumors...
  11. ncbi Lymphoid neogenesis in rheumatoid synovitis
    S Takemura
    Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 167:1072-80. 2001
    ....
  12. ncbi Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas
    A L Feldman
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:1139-43. 2008
    ....
  13. ncbi Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma
    Y Yoong
    Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 42:1235-41. 2001
    ..There is a subset of pts that have prolonged disease stabilization without the requirement for immediate chemotherapy after splenectomy...
  14. ncbi Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis
    J K Lim
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Pathol 54:642-6. 2001
    ..CONCLUSIONS: Pulmonary marginal zone lymphoma may be found in association with localised amyloid deposition and should be considered in the differential diagnosis of localised pulmonary amyloidosis...
  15. ncbi The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis
    C M Weyand
    Departments of Medicine and Immunology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Curr Opin Rheumatol 15:259-66. 2003
    ..Recent data support the concept that the tissue organization in the rheumatoid joint fosters a breakdown in self-tolerance by promoting a phase transition from self-limited immune responses to self-perpetuating autoimmune responses...
  16. ncbi NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis
    W G Morice
    Leukemia 20:883-6. 2006
  17. ncbi The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma
    E D Remstein
    Leukemia 22:1268-72. 2008
  18. ncbi Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1
    E D Remstein
    Divisions of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 18:156-60. 2004
    ..Ectopic nuclear bcl-10 expression is associated with API2-MALT1 but may also be seen in IGH-MALT1 fusion-positive, aneuploidy-only, and normal cases...
  19. ncbi Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2
    R R Einerson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 20:1790-9. 2006
    ..In light of the discovery of the distally located BVR2 breakpoint cluster region, it is important to use MYC FISH probes that cover a breakpoint region at least 1.0 Mb 3' of MYC...